Request Demo
Last update 18 Jul 2025
Lornoxicam
Last update 18 Jul 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Bevonium Metilsulfate, Bosporon, Chlortenoxicam + [20] |
Target |
Action inhibitors |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Denmark (01 Jan 1997), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC13H10ClN3O4S2 |
InChIKeyWLHQHAUOOXYABV-UHFFFAOYSA-N |
CAS Registry70374-39-9 |
Related
31
Clinical Trials associated with LornoxicamCTRI/2024/02/062947
Comparative evaluation of efficacy of single pre-emptive dose of Extended release Lornoxicam versus Prolonged release Diclofenac for surgical removal of impacted 3rd molar in Indian population: A prospective, randomized, triple blind, split mouth clinical trial. - NIL
NCT05679453
Comparison of Lornoxicam and Etodolac on Edema, Trismus and Pain After Third Molar Surgery
CTRI/2022/03/041484
EFFICACY OF PREOPERATIVE INTRAVENOUSLORNOXICAM ON ATTENUATING THEHEMODYNAMIC RESPONSES FOLLOWINGLARYNGOSCOPY AND ENDOTRACHEALINTUBATION
100 Clinical Results associated with Lornoxicam
Login to view more data
100 Translational Medicine associated with Lornoxicam
Login to view more data
100 Patents (Medical) associated with Lornoxicam
Login to view more data
1,237
Literatures (Medical) associated with Lornoxicam03 Jul 2025JOURNAL OF DRUG TARGETING
Formulation, optimisation, and evaluation of Lornoxicam-loaded Novasomes for targeted ulcerative colitis therapy: in vitro and in vivo investigations
Article
Author: Darwish, Asmaa Badawy ; Essam Ibrahim Al-Samadi, Inas ; Salama, Abeer
The purpose of this work was to create and assess Lornoxicam (LOR) loaded Novasomes (Novas) for the efficient treatment of ulcerative colitis. The study was performed using a 23 factorial design to investigate the impact of several formulation variables. Three separate parameters were investigated: Surface Active agent (SAA) type (X1), LOR concentration (X2), and SAA: Oleic acid ratio (X3). The dependent responses included encapsulation efficiency (Y1: EE %), particle size (Y2: PS), zeta potential (Y3: ZP), and polydispersity index (Y4: PDI). The vesicles demonstrated remarkable LOR encapsulation efficiency, ranging from 81.32 ± 3.24 to 98.64 ± 0.99%. The vesicle sizes ranged from 329 ± 9.88 to 583.4 ± 9.04 nm with high negative zeta potential values. The release pattern for Novas' LOR was biphasic and adhered to Higuchi's model. An in-vivo study assessed how LOR-Novas affected rats' acetic acid-induced ulcerative colitis (UC). The optimised LOR-Novas effectively reduced colonic ulceration (p < 0.05) and reduced the inflammatory pathway via inhibiting Toll-like receptor 4 (TLR4), Nuclear factor kappa β (NF-κβ) and inducible nitric oxide (iNO). At the same time, it elevated Silent information regulator-1(SIRT-1) and reduced glutathione (GSH) colon contents. Thus, the current study suggested that the formulation of LOR-Novas may be a viable treatment for ulcerative colitis.
01 Jul 2025JOURNAL OF MOLECULAR LIQUIDS
A sustainable and comprehensive protocol for spectrofluorimetric assay of lornoxicam in pharmaceutical dosage forms using biomass-based carbon dots: Evaluation of whiteness, greenness, and blueness of the methodology
Author: katamesh, Noha S. ; Abdel-Lateef, Mohamed A. ; Gomaa, Hassanien ; Darwish, Ibrahim A.
In this study, water-soluble carbon dots (B-CDs) were synthesized from the peel of red pitaya fruits.The synthesized B-CDs were characterized and recognized by optical, microscopical, and spectroscopical techniques.In addition, the quantum yield of the prepared B-CDs was determinedThe prepared B-CDs exhibit distinctive fluorescence spectra at 369.5 nm and 441.5 nm for excitation and emission, resp.On the other hand, lornoxicam exhibits a UV-absorbance spectrum with the highest peak of 370 nm, which thoroughly overlapped with fluorescence excitation of the prepared B-CDs and competed with its absorption.Consequently, the fluorescence of the prepared B-CDs was quenched, and a novel fluorescence anal. method was developed to determine lornoxicam based on the primary inner filter effect mechanism.The validation of the method exhibited a linearity of 1.5-12.0 μg/mL with a detection limit of 0.405 μg/mL in addition to satisfactory recovery and accuracy.The study has effectively measured the amount of lornoxicam in different types of pharmaceutical dosage forms.Moreover, to ensure environmental sustainability, greener solvents were chosen in place of hazardous solvents, utilizing the Green Solvents Selecting Tool.Anal. Eco scale, NEMI, AGREE and Agree prep algorithms, SPMS, and Complex-GAPI, as well as an extensive greenness anal., proved the technique′s advantageous ecol. characteristics.In addition, the recent RGB12 and BAGI algorithms were applied to evaluate the greenness framework and were introduced as tools for examining the "whiteness" and "blueness" of the work.
01 Jun 2025INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Multimodal evaluation of lipoxygenase-targeting NSAIDs using integrated in vitro, SAR, in silico, cytotoxicity towards MCF-7 cell line, DNA docking and MD simulation approaches
Article
Author: Hayat, Muhammad Munawar ; Ashraf, Muhammad ; Ejaz, Samina ; Iqbal, Ambar ; Riaz, Naheed ; Abbas, Wasim ; Ashok, Avinash Karkada
Lipoxygenase (LOX) and cyclooxygenase (COX) pathways generate biologically active mediators implicated in inflammatory disorders and several classes of cancer. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the COX pathway by inhibiting the COX-1 and COX-2 enzymes. We reported earlier that several NSAIDs, including naproxen, aspirin and acetaminophen, inhibited lipoxygenase (LOX) enzyme at sub-micromolar concentrations. In continuation, the present work demonstrates the anti-LOX activity of nine more NSAIDs supported by in vitro, in silico, MD simulation and breast cancer cell line studies. All tested drugs displayed potent to excellent inhibitory profiles with IC50 values <24.93 ± 0.64 μM. Aceclofenac (IC50 0.85 ± 0.06 μM) was the most active drug, followed by indomethacin (IC50 1.13 ± 0.07 μM), meloxicam (IC50 1.94 ± 0.07 μM) and ketorolac (IC50 9.26 ± 0.82 μM). Celecoxib (IC50 15.81 ± 0.71 μM), lornoxicam (IC50 16.54 ± 0.28 μM) and nimesulide (IC50 19.87 ± 0.85 μM) showed excellent inhibitory profiles. Flurbiprofen (IC50 21.73 ± 0.93 μM) and etoricoxib (IC50 24.93 ± 0.64 μM) moderately inhibited the target enzyme. SAR studies revealed that active molecules decorated with the carboxylate group afforded strong binding interactions as observed by in vitro assays and structural features. Other drugs, including enol derivatives and celecoxib, also showcased enhanced binding interactions. However, the cytotoxic effects of NSAIDs against the MCF-7 breast cancer cell line did not disclose significant anticancer activity. Molecular docking studies against human 5-LOX offered the best binding affinities for aceclofenac (-13.54 kcal/mol), accompanied by conventional hydrogen bonding and hydrophobic interactions as supported by the in vitro results. Docking studies with DNA dodecamer established minor groove binding with their possible role in DNA replication and gene expression. Density functional theory (DFT) and ESP studies, MD simulations and MMPBSA free energy calculations further reiterated the stability of ligand-receptor complexes. Overall, these findings highlight the potential of targeted NSAIDs as dual COX/LOX inhibitors with broader therapeutic relevance in inflammatory disorders.
2
News (Medical) associated with Lornoxicam
100 Deals associated with Lornoxicam
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01866 | Lornoxicam |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Bursitis | Japan | 02 Feb 2001 | |
| Cervicobrachial syndrome | Denmark | - | 01 Jan 1997 |
| Low Back Pain | Denmark | - | 01 Jan 1997 |
| Neuralgia | Denmark | - | 01 Jan 1997 |
| Osteoarthritis | Denmark | - | 01 Jan 1997 |
| Pain | Denmark | - | 01 Jan 1997 |
| Pain, Postoperative | Denmark | - | 01 Jan 1997 |
| Periarthritis | Denmark | - | 01 Jan 1997 |
| Rheumatic Diseases | Denmark | - | 01 Jan 1997 |
| Rheumatoid Arthritis | Denmark | - | 01 Jan 1997 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Headache | Phase 2 | United States | 01 Dec 2005 | |
| Migraine Disorders | Phase 2 | United States | 01 Dec 2005 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 219 | (Lornoxicam) | ywpeplgaow(aoaexrfkop) = bqtlcauvly tflpmgomrz (rjiwgfaujy, 6.75) View more | - | 29 Nov 2012 | ||
Placebo (Placebo) | ywpeplgaow(aoaexrfkop) = usdmksfard tflpmgomrz (rjiwgfaujy, 7.84) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free